Hepatitis B cost-effectiveness of therapy

Revision as of 19:02, 30 July 2014 by Joao Silva (talk | contribs)
Jump to navigation Jump to search

Hepatitis Main Page

Hepatitis B

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis B from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatitis B cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis B cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis B cost-effectiveness of therapy

CDC on Hepatitis B cost-effectiveness of therapy

Hepatitis B cost-effectiveness of therapy in the news

Blogs on Hepatitis B cost-effectiveness of therapy

Directions to Hospitals Treating Hepatitis B

Risk calculators and risk factors for Hepatitis B cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Attending to the inceased risk of developing complications, such as cirrhosis or hepatocellular carcinoma, in infants and young children who are infected with the HBV and the benefits of vaccination and postexposure prophylaxis, the prevention and treatment of hepatitis B are considered cost-effective.

References

Template:WH Template:WS